Proprietary in Medical Technology

Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data

WARRENDALE, Pa., May 18 /PRNewswire/ -- MEDRAD Interventional(TM)/Possis(R) today announced that it has reached key milestones in bringing the Paccocath(R) Technology closer to market as an option for the over 14 million patients in the United States and Europe who suffer from Peripheral Arterial ...

Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI

Angiomax Will Remain the NSTEMI Market Share Leader Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy...

Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed

CAMBRIDGE, Mass. and COLUMBUS, Ohio, Jan. 8 /PRNewswire/ --IntelligentMDx a developer and manufacturer of proprietary nucleic acid assays, today announced that verification studies of the IntelligentMDx BK Viral Quantitative Assay are complete. Under the verification protocol the Limit of De...

Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

Quark siRNAs Examined Alone and in Combination with Chemotherapy FREMONT, Calif. Oct. 12 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cance...

Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress

Findings Confirm Potency of Poly-ICR as Vaccine Adjuvant SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today presented positive data from preclinical studies using its proprietary Toll-like Receptor 3 agonist, Poly IC-Poly Arginine (Poly-I...

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)

- Improved Pharmacokinetic Characteristics of Naltrexone SR Associated with Better Tolerability in Clinical Trials - PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity and other ce...

Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property

Data Validates Neuroprotective Effect of Quark's New RNAi Product on Dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma FREMONT, Calif., Sept. 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interfere...

AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform

AMSTERDAM, The Netherlands, September 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Par...

Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform

ORMD 0901 is Being Developed as an Oral Dosage Form of a GLP1-analog Aimed at Improving Glycemic Control in Adults With Type 2 Diabetes JERUSALEM, Israel, September 16 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral drug delivery systems, announ...

First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval

Test Developed and Validated by Columbia University Medical Center Based on Rosetta Genomics' Proprietary MicroRNA Technology The Test Differentiates Squamous From Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying Squamous-Cell Carcinoma of the Lung With Sensitivity...

Nventa Develops Proprietary Vaccine Adjuvant

Potent Adjuvant is a Toll-Like Receptor 3 (TLR3) Agonist SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the company has developed a proprietary vaccine adjuvant, Poly IC-Poly Arginine (Poly-ICR), that has broad potenti...

Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development

ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has created a new proprietary process to develop a vaccine candidate against Severe Acute Respiratory Syndrome (SARS). The company also received renewed research funding from the National Inst...

New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume

KGK Synergize Inc. Presents Findings Today SAN DIEGO, April 7, 2008 /PRNewswire/ -- A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol(TM), produces a pronounced reduction of malignant melanoma cell gro...

Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica

The Laboratory-Developed Test is Designed to Differentiate Squamous From Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying Squamous Cell Carcinoma of the Lung With Sensitivity of 96 Percent and Specificity of 90 Percent. Accurate Diagnosis is Importa...

Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research

BETHESDA, Md., March 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that five posters will be presented on April 14, 2008, at the ann...

Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss

Quark Expands Hearing Loss Program With Novel SiRNA Approaches To Noise- Induced Hearing Loss With Its First Drug Candidate, AHLI-11, For The Prevention Of Chemotherapy-Induced Hearing Loss In Late Pre-IND Stage FREMONT, Calif., Sept. 24 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clini...

Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss

Quark's First Hearing Loss Compound, AHLi-11, Slated for IND Filing By Year- End 2007 FREMONT, Calif., Aug. 20 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based...

Integrated BioPharma's Proprietary Vaccine Technology Achieves Strong Positive Results

HILLSIDE, NJ, March 12, 2007—InB:Biotechnologies, Inc. ("BioTech"), a wholly-owned subsidiary of Integrated BioPharma, Inc. (NASDAQ: INBP), today announced strong positive results in studies of vaccines against HPV, anthrax and plague made using INBP's novel, proprietary AIPwLV™ vaccin...

Integrated Biopharma's Proprietary Vaccine Technology Achieves Strong Positive Results

HILLSIDE, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- InB:Biotechnologies, Inc. ("BioTech"), a wholly-owned subsidiary of Integrated BioPharma, Inc. , today announced strong positive results in studies of vaccines against HPV, anthrax and plague made using INBP's novel, proprietary AIPwLV(TM) v...

Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention

BOTHELL, Wash., April 18, 2007 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc. today announced that Timothy Falla, Ph.D, Chief Scientific Officer, will present an update on the company's new generation of small molecule peptide (lipohexapeptide) technology at the BIO International Convention. The c...

Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR

BOTHELL, Wash. & LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data from fifteen presentations by the company and its collaborators at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) demonstrating preclinical ad...

Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--May 23, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 and Phase 2a clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, were presented today at the American Psychiatric Association (APA...

Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, were presented today at the SLEEP 2007 Annual Meeting of the Associated Profes...

Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 13, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 and Phase 2a clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, were presented in two sessions at the SLEEP 2007 Annual Meeting o...

Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin(R) technology has successfully demonstrated dual targeting potential....

Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 25, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced positive top-line results from two dose-ranging, Phase 2b clinical trials in chronic insomnia patients with the Company's proprietary insomnia agent, NG2-73, an alpha-3 preferring GABA(A) partial ag...

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma....

NewCardio Announces Master Services Agreement With Dedicated Phase I

...s a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value o... and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing an...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

...n their lives. About Labopharm Inc. Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the ...

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

...clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing ap...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...and our successful strategy to focus on developing proprietary drugs with our advanced polymer conjugate technolo...ed positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines N...rogress and potential of the company's pipeline of proprietary drug candidates, the value and potential of the co...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...r-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP((R)), which enables the rapid and efficient discovery of small molecule drug candidates. TELIK, the Telik logo,...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...e. INVEGA(R) SUSTENNA(TM) was developed utilizing Elan Drug Technologies' proprietary NanoCrystal((R)) Technology. Using this technology increases the rate of di...VEGA(R) SUSTENNA(TM) utilizes the NanoCrystal((R)) Technology, which is a proprietary technology developed by Elan Drug Technologies through Elan Pharma Internat...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

...tis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an a...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

...r 100 patients at 24 sites in 10 countries around the world have participated in the clinical studies. Velaglucerase alfa is made using Shire's proprietary technology, in a human cell line. The enzyme produced has the exact human amino acid sequence and carries a human glycosylation pattern. Phase ...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

... the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for...ion symptoms." "BCI-952 was selected by our proprietary platform for the compound's neurogenic properties,...esearch of neurogenesis by applying its robust and proprietary platform technology to identify novel pathways for...

Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.

...axis to conduct clinical studies using Cryo-Cell's proprietary C'elle(SM) menstrual stem technology (MenSCs) to i...m cells, which will be collected using Cryo-Cell's proprietary C'elle system. "This research will determi...ion and potential commercialization of Cryo-Cell's proprietary C'elle menstrual stem cell technology in the futur...

First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center

...tem is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Utilizing a proprietary miniaturized X-ray source and robotic controller, treatment can be performed in minimally shielded therapeutic settings allowing the radiation oncolog...

CareFirst BCBS Covers eNO Measurement for Diagnosis, Asthma Treatment

... About the Insight eNO System The Insight eNO System has been available for use in the physician's office since March 2008. The system uses a proprietary biosensor technology to measure exhaled nitric oxide, a well established indicator of asthma severity and steroid responsive airway inflammation. Meas...

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

...noid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated...